Patent details
301098
Product Name:
crizanlizumab
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301098
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2662091
Status:
Application Pending
Application number:
301098
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)
Marketing Authorization
Marketing Authorization Number:
EU/1/20/1476
Marketing Authorization Type:
EEA
Marketing Authorization Date:
29/10/2020
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
01/04/2021
First Marketing Authorization date:
29/10/2020
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
01/04/2021
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
01/04/2021
Name:
Novartis AG
Address:
Lichtstrasse 35, 4056, BASEL, Switzerland (CH)
From:
01/04/2021
Name:
Oklahoma Medical Research Foundation
Address:
825 N.E. 13th Street, 73104, Oklahoma City, Oklahoma, United States of America (US)
Agent
1
Name:
dr. R.C. van Duijvenbode c.s.
From:
07/11/2025
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
2
Name:
ir. M.F.J.M. Ketelaars c.s.
From:
01/04/2021
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
07/11/2025
Publication
Bulletin
Bulletin Heading:
SPC
Journal edition number:
14/21
Publication date:
07/04/2021
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
12/02/2026
Incoming Correspondence Electronic
Request extension time-limit modifications
1
PDF
/4/7/6/3/6/0800663674/docs/301098_6_incomingcorrespondenceelectronic20260212102816408.pdf
12/02/2026
Outgoing Correspondence
Letter to applicant
1
PDF
/4/7/6/3/6/0800663674/docs/301098_7_301098695476l173.pdf
12/02/2026
Incoming Correspondence Electronic
Accompanying letter incoming document
6
PDF
/4/7/6/3/6/0800663674/docs/301098_8_incomingcorrespondenceelectronic20260213014547037.pdf
12/02/2026
SPC Documents
Annex SPC
3
PDF
/4/7/6/3/6/0800663674/docs/301098_9_supplprotectioncertificate20260213014746018.pdf
12/02/2026
SPC Documents
Annex SPC
8
PDF
/4/7/6/3/6/0800663674/docs/301098_10_supplprotectioncertificate20260213014700259.pdf
12/02/2026
SPC Documents
Annex SPC
3
PDF
/4/7/6/3/6/0800663674/docs/301098_11_supplprotectioncertificate20260213014621425.pdf
20/11/2025
Outgoing Correspondence
Letter to applicant
2
PDF
/4/7/6/3/6/0800663674/docs/301098_5_301098683440l173.pdf
06/04/2021
Outgoing Correspondence
Confirmation receipt request
1
PDF
/4/7/6/3/6/0800663674/docs/301098_1_403790l174.pdf
01/04/2021
SPC Documents
Summary of the characteristics of the product
14
PDF
/4/7/6/3/6/0800663674/docs/301098_0_supplprotectioncertificate20210401025353088.pdf
01/04/2021
SPC Documents
Annex SPC
2
PDF
/4/7/6/3/6/0800663674/docs/301098_2_supplprotectioncertificate20210401025245819.pdf
01/04/2021
SPC Documents
Marketing Authorization SPC
3
PDF
/4/7/6/3/6/0800663674/docs/301098_3_supplprotectioncertificate20210401025154476.pdf
01/04/2021
Application Form
First filed application form
2
PDF
/4/7/6/3/6/0800663674/docs/301098_4_applicationform20210401024704098.pdf